https://www.pharmaradar360.com/article/circle-u-universite-paris-cite-is-recruiting-for-its-new-democracy-chair-de1bad9a83576c23Pharma Surgeen2026-07-01T11:16:02.000ZCircle U.: Université Paris Cité is recruiting for its new ‘Democracy’ chairhttps://www.pharmaradar360.com/article/medical-journal-retracts-tavneos-pivotal-paper-amid-wider-regulatory-clampdown-488ee88452b0e749Pharma Surgeen2026-07-01T11:07:48.000ZMedical journal retracts Tavneos pivotal paper amid wider regulatory clampdownhttps://www.pharmaradar360.com/article/prac-juni-2026-herziening-afgerond-van-veiligheidssignaal-over-valproaat-en-verw-9c15f77ecd083172Pharma Surgeen2026-07-01T11:06:59.000ZPRAC juni 2026: herziening afgerond van veiligheidssignaal over valproaat en verwante stoffen en aanbeveling voor gezondheidszorgbeoefenaars met nieuwe veiligheidsgegevens over chikungunya-vaccin Ixchiqhttps://www.pharmaradar360.com/article/sompo-c465f6e6bb9e5003Pharma Surgeen2026-07-01T11:00:00.000Z「SOMPOサステナビリティ・インデックス」の構成銘柄に選定https://www.pharmaradar360.com/article/inverclyde-public-holiday-reminder-e98fb11105e32977Pharma Surgeen2026-07-01T10:50:02.000ZInverclyde public holiday reminderhttps://www.pharmaradar360.com/article/lonza-expands-manufacturing-capacity-for-hpapi-and-adc-payload-linkers-9f08463e6065aebdPharma Surgeen2026-07-01T10:34:30.000ZLonza expands manufacturing capacity for HPAPI and ADC payload-linkershttps://www.pharmaradar360.com/article/new-transatlantic-research-network-athena-advances-mechanistic-insights-and-tran-61bb4e4f270fad00Pharma Surgeen2026-07-01T10:20:42.000ZNew transatlantic research network ATHENA advances mechanistic insights and translational applications in cardiovascular diseasehttps://www.pharmaradar360.com/article/prof-mesias-alfeus-s-vision-brings-global-finance-congress-to-africa-9e6ee115bd5ab49bPharma Surgeen2026-07-01T10:19:03.000ZProf Mesias Alfeus’s vision brings global finance congress to Africahttps://www.pharmaradar360.com/article/telum-raises-18-million-euros-for-hospital-pneumonia-program-6ca41f650918e4c2Pharma Surgeen2026-07-01T10:15:07.000ZTelum raises 18 million euros for hospital pneumonia programhttps://www.pharmaradar360.com/article/alzecure-lands-2-2-billion-neurorestore-licensing-deal-72c21c4570dad3dcPharma Surgeen2026-07-01T10:15:07.000ZAlzeCure lands $2.2 billion NeuroRestore licensing dealhttps://www.pharmaradar360.com/article/new-drug-data-makes-this-french-biotech-stock-a-buy-says-jefferies-1dc8dc0b61b6a13bPharma Surgeen2026-07-01T10:12:10.000ZNew drug data makes this French biotech stock a buy, says Jefferieshttps://www.pharmaradar360.com/article/goldenwell-biotech-gwll-q1-2026-shows-loss-and-going-concern-warning-df74ecaf53929bfcPharma Surgeen2026-07-01T10:09:20.000ZGoldenwell Biotech (GWLL) Q1 2026 shows loss and going concern warninghttps://www.pharmaradar360.com/article/goldenwell-biotech-otcqb-gwll-flags-going-concern-risk-in-2025-cf13ce25a3877f74Pharma Surgeen2026-07-01T10:09:20.000ZGoldenwell Biotech (OTCQB: GWLL) flags going concern risk in 2025https://www.pharmaradar360.com/article/lilly-and-regeneron-amongst-first-incumbents-to-fda-s-fast-track-facility-scheme-adf9737b74e87ef3Pharma Surgeen2026-07-01T10:07:30.000ZLilly and Regeneron amongst first incumbents to FDA’s fast-track facility schemehttps://www.pharmaradar360.com/article/centogene-apac-office-official-opening-ceremony-in-taiwan-5e7c2f33ff3d28adPharma Surgeen2026-07-01T10:07:11.000ZCENTOGENE APAC Office Official Opening Ceremony in Taiwanhttps://www.pharmaradar360.com/article/goldenwell-biotech-inc-fy-2025-revenue-55-net-loss-296471-eps-2-99-10-k-summary-ea57dfc53f124f66Pharma Surgeen2026-07-01T10:05:01.000ZGOLDENWELL BIOTECH, INC. FY 2025: Revenue $55 Net loss $296471 EPS $(2.99) — 10-K Summaryhttps://www.pharmaradar360.com/article/goldenwell-biotech-inc-1q-2026-revenue-0-eps-0-00018-10-q-summary-71268ca281a05e1bPharma Surgeen2026-07-01T10:01:01.000ZGOLDENWELL BIOTECH, INC. 1Q 2026: Revenue $0 EPS $(0.00018) — 10-Q Summaryhttps://www.pharmaradar360.com/article/how-a-chinese-heart-could-get-us-blood-pumping-despite-biotech-decoupling-801466b4a21cfe26Pharma Surgeen2026-07-01T10:00:11.000ZHow a ‘Chinese heart’ could get US blood pumping despite biotech decouplinghttps://www.pharmaradar360.com/article/abivax-expands-obefazimod-safety-data-ahead-of-fda-filing-57029d6faeceac41Pharma Surgeen2026-07-01T09:59:59.000ZAbivax expands obefazimod safety data ahead of FDA filinghttps://www.pharmaradar360.com/article/4708-cabdf63b6a2f0e25Pharma Surgeen2026-07-01T09:37:59.000Z4708https://www.pharmaradar360.com/article/4707-8003cbbb2de7d330Pharma Surgeen2026-07-01T09:36:44.000Z4707https://www.pharmaradar360.com/article/europe-s-best-ai-literacy-initiative-for-education-comes-from-finland-cc45e34c3ae40328Pharma Surgeen2026-07-01T09:34:42.000ZEurope’s best AI literacy initiative for education comes from Finlandhttps://www.pharmaradar360.com/article/4706-4c09c5bdd99442bcPharma Surgeen2026-07-01T09:34:38.000Z4706https://www.pharmaradar360.com/article/the-quiet-winner-behind-the-ai-trade-biotech-s-2026-comeback-a723f4aa062804f0Pharma Surgeen2026-07-01T09:34:14.000ZThe Quiet Winner Behind the AI Trade: Biotech’s 2026 Comebackhttps://www.pharmaradar360.com/article/sicherung-des-erfahrungswissens-in-der-pflege-94aa1750c95dd382Pharma Surgeen2026-07-01T09:32:47.000ZSicherung des Erfahrungswissens in der Pflegehttps://www.pharmaradar360.com/article/cough-cold-877c2faa981b330bPharma Surgeen2026-07-01T09:25:44.000ZCough & coldhttps://www.pharmaradar360.com/article/pain-management-74e41bd83ec19eadPharma Surgeen2026-07-01T09:25:44.000ZPain managementhttps://www.pharmaradar360.com/article/neurology-a58b635c9e0a6948Pharma Surgeen2026-07-01T09:25:44.000ZNeurologyhttps://www.pharmaradar360.com/article/cardiometabolic-71013c17e503dc1fPharma Surgeen2026-07-01T09:25:44.000ZCardiometabolichttps://www.pharmaradar360.com/article/intim-health-eca7c77944742754Pharma Surgeen2026-07-01T09:25:44.000ZIntim healthhttps://www.pharmaradar360.com/article/gastroenterology-7cd4a508c75ee48ePharma Surgeen2026-07-01T09:25:44.000ZGastroenterologyhttps://www.pharmaradar360.com/article/skin-care-9aa94a454f51adf8Pharma Surgeen2026-07-01T09:25:44.000ZSkin carehttps://www.pharmaradar360.com/article/antibiotics-and-antiseptics-fa9bdda42fd922adPharma Surgeen2026-07-01T09:25:44.000ZAntibiotics and antisepticshttps://www.pharmaradar360.com/article/drugs-for-allergy-59a97128d8db45f3Pharma Surgeen2026-07-01T09:25:44.000ZDrugs for Allergyhttps://www.pharmaradar360.com/article/a86aeaacc0794fc2Pharma Surgeen2026-07-01T09:25:44.000ZПрепарати від застуди та температуриhttps://www.pharmaradar360.com/article/67fd799badde67b2Pharma Surgeen2026-07-01T09:25:44.000ZПрепарати від болю та запаленняhttps://www.pharmaradar360.com/article/7e50fbf1abda0ef5Pharma Surgeen2026-07-01T09:25:44.000ZНеврологічні препаратиhttps://www.pharmaradar360.com/article/711130ed8801dad3Pharma Surgeen2026-07-01T09:25:44.000ZКардіометаболічні препаратиhttps://www.pharmaradar360.com/article/093eccbbf126368dPharma Surgeen2026-07-01T09:25:44.000ZПрепарати для інтимного здоров'яhttps://www.pharmaradar360.com/article/4b0e5cd187e5d81bPharma Surgeen2026-07-01T09:25:44.000ZПрепарати для застосування у хірургіїhttps://www.pharmaradar360.com/article/936f09610928a995Pharma Surgeen2026-07-01T09:25:44.000ZГастроентерологічні препаратиhttps://www.pharmaradar360.com/article/a7acf071e3e232d9Pharma Surgeen2026-07-01T09:25:44.000ZДерматологічні препаратиhttps://www.pharmaradar360.com/article/5daddcfeb2c6c35aPharma Surgeen2026-07-01T09:25:44.000ZАнтибактеріальні препарати та антисептикиhttps://www.pharmaradar360.com/article/f8dbae610e164eebPharma Surgeen2026-07-01T09:25:44.000ZПрепарати при алергіїhttps://www.pharmaradar360.com/article/d3127f1a42d5f338Pharma Surgeen2026-07-01T09:25:44.000ZПрепаратиhttps://www.pharmaradar360.com/article/roderic-guigo-elected-to-the-embo-membership-56456b020e5b6af4Pharma Surgeen2026-07-01T09:21:14.000ZRoderic Guigó elected to the EMBO Membershiphttps://www.pharmaradar360.com/article/tutors-help-new-students-settle-into-their-new-environment-20eef4901c02eef6Pharma Surgeen2026-07-01T09:16:24.000ZTutors help new students settle into their new environmenthttps://www.pharmaradar360.com/article/national-chlamydia-screening-programme-ncsp-incident-reporting-policy-0672a64ca91c74c7Pharma Surgeen2026-07-01T09:15:55.000ZNational Chlamydia Screening Programme (NCSP): incident reporting policyhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-china-resources-pharmaceutical-group-ltd-hkex-3320-b0fd53eeffb32e34Pharma Surgeen2026-07-01T09:09:54.000ZPrice to earnings forward of China Resources Pharmaceutical Group Ltd. – HKEX:3320https://www.pharmaradar360.com/article/primare-hirntumoren-und-hirnmetastasen-neue-behandlungsansatze-85e14ef9b1b5131ePharma Surgeen2026-07-01T09:00:02.000ZPrimäre Hirntumoren und Hirnmetastasen: neue Behandlungsansätzehttps://www.pharmaradar360.com/article/can-glp-1-medications-improve-health-in-people-with-type-2-diabetes-and-pad-c7da23592ae37da3Pharma Surgeen2026-07-01T09:00:00.000ZCan GLP-1 medications improve health in people with Type 2 diabetes and PAD?https://www.pharmaradar360.com/article/beyond-the-glp-1ra-weight-loss-ceiling-bfdcd2789ab0565cPharma Surgeen2026-07-01T08:59:44.000ZBeyond the GLP-1RA weight loss ceilinghttps://www.pharmaradar360.com/article/massachusetts-biotech-layoffs-drop-to-lowest-level-in-over-two-years-3306c415e957eeecPharma Surgeen2026-07-01T08:50:00.000ZMassachusetts biotech layoffs drop to lowest level in over two yearshttps://www.pharmaradar360.com/article/tracking-cathie-wood-doubling-down-on-ai-biotech-and-crypto-retreating-from-geno-648a1d977138792fPharma Surgeen2026-07-01T08:41:21.000ZTracking Cathie Wood: Doubling Down on AI-Biotech and Crypto, Retreating From Genomics and China Techhttps://www.pharmaradar360.com/article/backed-by-top-tier-vcs-stealthy-biotech-bags-alzecure-alzheimer-s-asset-in-2-2b-a939ff27f66cd618Pharma Surgeen2026-07-01T08:40:40.000ZBacked by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer’s asset in $2.2B dealhttps://www.pharmaradar360.com/article/mrsa-mssa-gram-negative-bacteraemia-and-cdi-monthly-data-2025-to-2026-46183ecdfec674ccPharma Surgeen2026-07-01T08:30:01.000ZMRSA, MSSA, Gram-negative bacteraemia and CDI: monthly data, 2025 to 2026https://www.pharmaradar360.com/article/rsv-vaccination-expansion-of-eligibility-to-older-adults-in-certain-clinical-ris-35805c2e55b3981ePharma Surgeen2026-07-01T08:30:01.000ZRSV vaccination: expansion of eligibility to older adults in certain clinical risk groupshttps://www.pharmaradar360.com/article/pre-release-access-list-monthly-hcai-statistical-release-be74553657c78f7ePharma Surgeen2026-07-01T08:30:01.000ZPre-release access list: monthly HCAI statistical releasehttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-programme-7a9417a4fdf76e56Pharma Surgeen2026-07-01T08:30:01.000ZRespiratory syncytial virus (RSV) vaccination programmehttps://www.pharmaradar360.com/article/national-child-measurement-programme-operational-guidance-80a05d8f25e9c2b6Pharma Surgeen2026-07-01T08:30:00.000ZNational Child Measurement Programme: operational guidancehttps://www.pharmaradar360.com/article/national-child-measurement-programme-information-for-schools-aa4c279f547ed2b3Pharma Surgeen2026-07-01T08:30:00.000ZNational Child Measurement Programme: information for schoolshttps://www.pharmaradar360.com/article/ipsen-acquires-swiss-based-memo-therapeutics-501da5fb34e21753Pharma Surgeen2026-07-01T08:22:03.000ZIpsen acquires Swiss-based Memo Therapeuticshttps://www.pharmaradar360.com/article/oncologia-neurologia-infezioni-e-malattie-infiammatorie-al-policlinico-di-milano-4514604907a79162Pharma Surgeen2026-07-01T08:07:00.000ZOncologia, neurologia, infezioni e malattie infiammatorie: al Policlinico di Milano fabbrica hi-tech e radiofarmaci “in casa” per diagnosi rapide e cure personalizzatehttps://www.pharmaradar360.com/article/fda-seizes-adulterated-milk-dairy-products-and-sweets-worth-rs-13-71-lakh-2b04f2be00ce4925Pharma Surgeen2026-07-01T07:52:00.000ZFDA seizes adulterated milk, dairy products and sweets worth Rs 13.71 lakhhttps://www.pharmaradar360.com/article/imcd-opens-new-pharmaceutical-technical-centre-in-new-jersey-b80ea61c71e7a7eaPharma Surgeen2026-07-01T07:04:13.000ZIMCD opens new Pharmaceutical Technical Centre in New Jerseyhttps://www.pharmaradar360.com/article/golden-triangle-still-dominates-but-talent-and-capital-gaps-slow-biotech-growth-a53aa7d1cf5ae9abPharma Surgeen2026-07-01T07:01:33.000ZGolden Triangle still dominates, but talent and capital gaps slow biotech growthhttps://www.pharmaradar360.com/article/a-desire-to-make-a-difference-dr-davies-becomes-unmc-chancellor-f9cfe8c356910703Pharma Surgeen2026-07-01T07:00:00.000ZA desire to make a difference: Dr. Davies becomes UNMC chancellorhttps://www.pharmaradar360.com/article/several-open-access-publishing-agreements-approach-their-cap-bddc2dea2fff1fd1Pharma Surgeen2026-07-01T07:00:00.000ZSeveral Open Access publishing agreements approach their caphttps://www.pharmaradar360.com/article/causal-machine-learning-guided-personalized-immunochemotherapy-strategies-in-int-e07cee315f28a857Pharma Surgeen2026-07-01T07:00:00.000ZCausal machine learning–guided personalized immunochemotherapy strategies in intrahepatic cholangiocarcinoma (CMICC).https://www.pharmaradar360.com/article/an-integrative-multi-omics-machine-learning-framework-for-precision-metastasis-p-f0c26e3f1bf0d334Pharma Surgeen2026-07-01T07:00:00.000ZAn integrative multi-omics machine learning framework for precision metastasis prediction and clinical staging in non-small cell lung cancer.https://www.pharmaradar360.com/article/the-pan-sur-in-score-for-advanced-pancreatic-cancer-a-comprehensive-analysis-of-b10eb563897a0a31Pharma Surgeen2026-07-01T07:00:00.000ZThe PAN-SUR(IN) score for advanced pancreatic cancer: A comprehensive analysis of methodology, prognostic derivation, and clinical risk stratification.https://www.pharmaradar360.com/article/germline-testing-in-pancreatic-adenocarcinoma-a-retrospective-cohort-study-of-ge-12cb1dfba144ba07Pharma Surgeen2026-07-01T07:00:00.000ZGermline testing in pancreatic adenocarcinoma: A retrospective cohort study of germline genetic testing uptake, patterns of referral, clinical findings and impact in the South Western Sydney Local Health District.https://www.pharmaradar360.com/article/surgical-outcomes-and-recurrence-risk-factors-for-rectal-gastrointestinal-stroma-4e5f65ce9f8c2555Pharma Surgeen2026-07-01T07:00:00.000ZSurgical outcomes and recurrence risk factors for rectal gastrointestinal stromal tumors: A comparison of transabdominal and transanal resection.https://www.pharmaradar360.com/article/efficacy-and-safety-of-first-line-pd-1-pd-l1-inhibitor-based-therapy-in-esophage-9d69236d21c4a3f2Pharma Surgeen2026-07-01T07:00:00.000ZEfficacy and safety of first-line PD-1/PD-L1 inhibitor–based therapy in esophageal squamous cell carcinoma: A systematic review and meta-analysis.https://www.pharmaradar360.com/article/nodal-status-guided-postoperative-radiotherapy-after-neoadjuvant-chemoimmunother-923bd8032c10099aPharma Surgeen2026-07-01T07:00:00.000ZNodal status–guided postoperative radiotherapy after neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter cohort study.https://www.pharmaradar360.com/article/a-gan-based-multimodal-framework-for-preoperative-response-prediction-in-her2-ne-a938c97bc3dff159Pharma Surgeen2026-07-01T07:00:00.000ZA GAN-based multimodal framework for preoperative response prediction in HER2-negative locally advanced gastric cancer treated with neoadjuvant chemoimmunotherapy.https://www.pharmaradar360.com/article/neoadjuvant-chemotherapy-plus-serplulimab-and-immuno-response-molecular-subtype-468cf9db378240e7Pharma Surgeen2026-07-01T07:00:00.000ZNeoadjuvant chemotherapy plus serplulimab and immuno-response molecular subtype for pMMR locally advanced rectal cancer (FIRM).https://www.pharmaradar360.com/article/transformer-based-multi-omics-synthesis-for-early-risk-stratification-and-preven-811d0694e15987f6Pharma Surgeen2026-07-01T07:00:00.000ZTransformer-based multi-omics synthesis for early risk stratification and preventive surveillance in liver oncology.https://www.pharmaradar360.com/article/pathological-complete-response-after-neoadjuvant-chemoimmunotherapy-with-toripal-9bf56415c107f3d0Pharma Surgeen2026-07-01T07:00:00.000ZPathological complete response after neoadjuvant chemoimmunotherapy with toripalimab or camrelizumab in esophageal squamous cell carcinoma: A systematic review and meta-analysis.https://www.pharmaradar360.com/article/hepatic-arterial-infusion-chemotherapy-plus-immune-checkpoint-inhibitors-and-len-3154f847c04f1409Pharma Surgeen2026-07-01T07:00:00.000ZHepatic arterial infusion chemotherapy plus immune checkpoint inhibitors and lenvatinib for locally advanced biliary tract cancer: A single-arm, exploratory study.https://www.pharmaradar360.com/article/adebrelimab-plus-interventional-and-targeted-therapy-for-unresectable-hepatocell-bf49a7f692682f35Pharma Surgeen2026-07-01T07:00:00.000ZAdebrelimab plus interventional and targeted therapy for unresectable hepatocellular carcinoma: A single-arm, real-world study.https://www.pharmaradar360.com/article/neoadjuvant-anti-pd-1-monotherapy-in-msi-h-locally-advanced-gastric-cancer-3-yea-b2da7b3f63a1226bPharma Surgeen2026-07-01T07:00:00.000ZNeoadjuvant anti-PD-1 monotherapy in MSI-H locally advanced gastric cancer: 3-Year survival without surgery.https://www.pharmaradar360.com/article/relb-ilf2-gm-csf-loop-to-sustain-mdsc-mediated-prostate-cancer-immunosuppression-a8621ede2c828cc1Pharma Surgeen2026-07-01T07:00:00.000ZRelB/ILF2–GM-CSF loop to sustain MDSC-mediated prostate cancer immunosuppression.https://www.pharmaradar360.com/article/endoscopic-submucosal-dissection-for-early-gastrointestinal-neoplasms-a-prospect-e4d90bb182e6bc07Pharma Surgeen2026-07-01T07:00:00.000ZEndoscopic submucosal dissection for early gastrointestinal neoplasms: A prospective study of 50 cases in 45 patients in Vietnam.https://www.pharmaradar360.com/article/circulating-tumor-suppressor-micrornas-as-minimally-invasive-biomarkers-for-earl-6afb151f24bf95c0Pharma Surgeen2026-07-01T07:00:00.000ZCirculating tumor suppressor microRNAs as minimally invasive biomarkers for early detection of colorectal cancer.https://www.pharmaradar360.com/article/addressing-radiologist-inter-reader-variability-in-gastric-cancer-t-staging-a-pr-efbfbef113a7164aPharma Surgeen2026-07-01T07:00:00.000ZAddressing radiologist inter-reader variability in gastric cancer T staging: A prospective study using the dual-module AI model, TRACE.https://www.pharmaradar360.com/article/68ga-nodaga-sna009-a-first-in-class-single-domain-antibody-probe-for-rapid-pet-i-4f909e0e3885afd5Pharma Surgeen2026-07-01T07:00:00.000Z68Ga-NODAGA-SNA009: A first-in-class single-domain antibody probe for rapid PET imaging of GPA33 in colorectal cancer.https://www.pharmaradar360.com/article/liposomal-irinotecan-hr070803-plus-fluorouracil-and-bevacizumab-as-second-line-t-b455f1f72e55aa43Pharma Surgeen2026-07-01T07:00:00.000ZLiposomal irinotecan (HR070803) plus fluorouracil and bevacizumab as second-line treatment in advanced colorectal cancer: Cohort A results from a phase 2 trial.https://www.pharmaradar360.com/article/family-discovers-crucial-information-through-genetic-insights-project-34c2dce6d1b7bbd6Pharma Surgeen2026-07-01T06:58:00.000ZFamily discovers crucial information through Genetic Insights Projecthttps://www.pharmaradar360.com/article/submissions-for-healing-arts-staff-exhibition-due-july-31-6969fa3572ed3d26Pharma Surgeen2026-07-01T06:56:00.000ZSubmissions for Healing Arts staff exhibition due July 31https://www.pharmaradar360.com/article/unsicher-bei-der-hpv-impfung-2e1c02affd8979b4Pharma Surgeen2026-07-01T06:45:57.000ZUnsicher bei der HPV-Impfung?https://www.pharmaradar360.com/article/pole-dentaire-des-hus-l-expertise-des-chirurgien-dentistes-des-hus-au-service-de-612bb6989792b7baPharma Surgeen2026-07-01T06:30:00.000ZPôle dentaire des HUS : l’expertise des chirurgien dentistes des HUS au service des patients âgéshttps://www.pharmaradar360.com/article/chugai-pharmaceutical-opens-south-san-francisco-research-hub-to-facilitate-acade-3832bcb391aee635Pharma Surgeen2026-07-01T06:07:52.000ZChugai Pharmaceutical Opens South San Francisco Research Hub to Facilitate Academic Collaborationshttps://www.pharmaradar360.com/article/9-4-ab3ad7fbfaa51da3Pharma Surgeen2026-07-01T06:00:41.000Z厚生労働省臨床研究総合促進事業 監査担当者養成研修ー初級編ー開催のお知らせ(9/4開催)https://www.pharmaradar360.com/article/vgr-s-budget-for-2027-tydligare-krav-pa-resultat-b721095f28ca3fa2Pharma Surgeen2026-07-01T06:00:16.000ZVGR:s budget för 2027: tydligare krav på resultathttps://www.pharmaradar360.com/article/keti-koti-2026-commemorating-and-celebrating-334f783a3f5fa41bPharma Surgeen2026-07-01T05:58:19.000ZKeti Koti 2026: commemorating and celebratinghttps://www.pharmaradar360.com/article/ipsen-to-buy-swiss-biotech-memo-in-deal-that-could-top-800-million-73876289c22bac33Pharma Surgeen2026-07-01T05:55:00.000ZIpsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Millionhttps://www.pharmaradar360.com/article/nicox-s-ncx-470-new-drug-application-submitted-in-the-united-states-by-kowa-with-594db60965f7b910Pharma Surgeen2026-07-01T05:40:24.000ZNicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Paymenthttps://www.pharmaradar360.com/article/french-biotech-ipsen-to-buy-memo-therapeutics-for-230-million-upfront-6da978da538b6a1cPharma Surgeen2026-07-01T05:17:00.000ZFrench biotech Ipsen to buy Memo Therapeutics for $230 million upfronthttps://www.pharmaradar360.com/article/new-haven-biotech-company-developing-measles-treatment-as-us-cases-top-2-100-847db1483fa2587ePharma Surgeen2026-07-01T05:15:05.000ZNew Haven biotech company developing measles treatment as US cases top 2,100https://www.pharmaradar360.com/article/kirsten-detrick-a-connective-tissue-across-biotech-692a028db0e2880aPharma Surgeen2026-07-01T05:02:51.000ZKirsten Detrick: A connective tissue across biotechhttps://www.pharmaradar360.com/article/eucope-strengthens-its-expertise-on-joint-clinical-assessments-with-the-appointm-677515b55345a241Pharma Surgeen2026-07-01T05:00:33.000ZEUCOPE strengthens its expertise on Joint Clinical Assessments with the appointment of Dr. Thomas Eckerhttps://www.pharmaradar360.com/article/ways-to-reduce-legionella-risk-0d337c650a9a92c9Pharma Surgeen2026-07-01T04:56:59.000ZWays to reduce Legionella riskhttps://www.pharmaradar360.com/article/trinity-biotech-s-trinovium-secures-open-compute-project-membership-advancing-hy-4542b73f25657fd4Pharma Surgeen2026-07-01T04:24:03.000ZTrinity Biotech’s Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Coolinghttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-fujichenon-2c46eb29a72448a1Pharma Surgeen2026-07-01T03:00:00.000Z[SHINSA]English Translation of Review Report: Fujichenonhttps://www.pharmaradar360.com/article/shinsa-software-as-a-medical-device-samd-page-updated-7fd97df80e5d58f5Pharma Surgeen2026-07-01T03:00:00.000Z[SHINSA]Software as a Medical Device (SaMD) page updatedhttps://www.pharmaradar360.com/article/amed-8-3-7-22-9b702660cae90405Pharma Surgeen2026-07-01T02:59:59.000Z【AMED】令和8年度「革新的がん医療実用化研究事業」に係る公募（3次公募）のご案内［7月22日（水）正午締切］https://www.pharmaradar360.com/article/aribio-independently-completes-global-phase-3-trial-of-oral-alzheimer-s-drug-can-3f044d99763bdb8aPharma Surgeen2026-07-01T02:15:16.000ZAriBio Independently Completes Global Phase 3 Trial of Oral Alzheimer's Drug Candidate 'AR1001'https://www.pharmaradar360.com/article/menicon-group-strengthens-its-sales-foundation-in-eastern-japan-and-creates-new-96ceecc63adbddbbPharma Surgeen2026-07-01T01:00:00.000Z- Menicon Group strengthens its sales foundation in eastern Japan and creates new customer touchpoints -Announcement of stock acquisition of Inter-Optical Co., Ltd.https://www.pharmaradar360.com/article/shoko-co-ltd-began-commercial-production-of-pharmaceutical-excipient-viscomedi-a-73a8d5aeb77ebe90Pharma Surgeen2026-07-01T01:00:00.000ZShoko Co., Ltd. Began Commercial Production of Pharmaceutical Excipient “Viscomedi” at Its South Korean Planthttps://www.pharmaradar360.com/article/abvx-stock-clocks-best-day-in-11-months-on-analyst-upgrades-after-fresh-data-eas-d46907f9026ac411Pharma Surgeen2026-07-01T00:13:00.000ZABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concernshttps://www.pharmaradar360.com/article/recce-pharmaceuticals-bolsters-cash-position-with-a-3-67-million-tax-refund-ahea-251fd09026122760Pharma Surgeen2026-07-01T00:07:10.000ZRecce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestoneshttps://www.pharmaradar360.com/article/nova-direcao-do-instituto-de-quimica-assume-com-compromisso-de-fortalecer-ensino-89b1a8ac9655b75fPharma Surgeen2026-07-01T00:02:41.000ZNova direção do Instituto de Química assume com compromisso de fortalecer ensino, pesquisa e inovaçãohttps://www.pharmaradar360.com/article/sns-565a0852bc6b80d8Pharma Surgeen2026-07-01T00:00:00.000Z当社名をかたるSNSなりすましアカウントに関する注意喚起https://www.pharmaradar360.com/article/2026-ec070bb469b928a1Pharma Surgeen2026-07-01T00:00:00.000Z「健康経営優良法人2026（大規模法人部門）」に認定https://www.pharmaradar360.com/article/s-p-global-sustainability-yearbook-member-2026-279f05c054bd9481Pharma Surgeen2026-07-01T00:00:00.000ZS&P GlobalによるSustainability Yearbook Member 2026に選定https://www.pharmaradar360.com/article/stn1012700-ryjusea-0-25mg-ml-0ed953aba75cf339Pharma Surgeen2026-07-01T00:00:00.000Z近視の進行抑制を目的とする点眼剤STN1012700（Ryjusea 0.25mg/mL点眼液）についてアジア事業地域で初めてとなる販売承認をフィリピンで取得https://www.pharmaradar360.com/article/0-02-0f9a27bb31a9a203Pharma Surgeen2026-07-01T00:00:00.000Z緑内障・高眼圧症治療剤「ロープレッサ®点眼液0.02%」国内における製造販売承認を取得https://www.pharmaradar360.com/article/80557f7187a4005dPharma Surgeen2026-07-01T00:00:00.000Z「ちびまる子ちゃん」と考える、子どもの近視 ― 日常の気づきから“まずは眼科へ”を伝える疾患啓発メッセージを全国に展開 ―https://www.pharmaradar360.com/article/santen-5-183cebec954fb527Pharma Surgeen2026-07-01T00:00:00.000ZSanten中国、5つの緑内障点眼薬について、中国本土における独占的な流通および販売促進に関する契約を締結https://www.pharmaradar360.com/article/0-1-220382c57ff2118aPharma Surgeen2026-07-01T00:00:00.000Z後天性眼瞼下垂治療剤「アップニーク®ミニ点眼液0.1%」発売のお知らせhttps://www.pharmaradar360.com/article/3e2f5afb2998a486Pharma Surgeen2026-07-01T00:00:00.000Z役員人事に関するお知らせhttps://www.pharmaradar360.com/article/8-edee54b10ac969f7Pharma Surgeen2026-07-01T00:00:00.000Z＜花粉症に対する意識調査＞ 花粉症で「パフォーマンスに影響あり」は8割以上 「初期療法（早期治療）」を正しく知っている人の半数以上は「毎年実施」 ～眼科医と気象予報士が解説、花粉飛散期前の対策で春をより快適に～https://www.pharmaradar360.com/article/40-mg-ml-f2e91aca82d2272cPharma Surgeen2026-07-01T00:00:00.000Zアフリベルセプト硝子体内注射用キット40 mg/mL「バイエル」の発売予定についてhttps://www.pharmaradar360.com/article/new-draft-pmos-guideline-recommends-annual-review-and-could-mean-quicker-diagnos-7d655745f0e8ce05Pharma Surgeen2026-07-01T00:00:00.000ZNew draft PMOS guideline recommends annual review and could mean quicker diagnosishttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-01T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/just-how-goal-directed-are-hippocampal-theta-sweeps-anyway-b37855d6d2c0dbb5Pharma Surgeen2026-07-01T00:00:00.000ZJust how goal-directed are hippocampal theta sweeps, anyway?https://www.pharmaradar360.com/article/hippocampal-theta-sweeps-indicate-goal-direction-during-navigation-b11cf136bcf3d8c1Pharma Surgeen2026-07-01T00:00:00.000ZHippocampal theta sweeps indicate goal direction during navigationhttps://www.pharmaradar360.com/article/goal-directed-hippocampal-theta-sweeps-during-memory-guided-navigation-a4e197b2ee14c68ePharma Surgeen2026-07-01T00:00:00.000ZGoal-directed hippocampal theta sweeps during memory-guided navigationhttps://www.pharmaradar360.com/article/a-meta-analysis-of-the-long-term-effects-of-antihypertensive-therapy-on-the-risk-e7e08093a49e582fPharma Surgeen2026-07-01T00:00:00.000ZA meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trialshttps://www.pharmaradar360.com/article/blood-based-circular-rnas-for-early-diagnosis-of-alzheimer-s-disease-68505ce9c2e3bb9dPharma Surgeen2026-07-01T00:00:00.000ZBlood-based circular RNAs for early diagnosis of Alzheimer’s diseasehttps://www.pharmaradar360.com/article/innate-immune-responsiveness-predicts-enhanced-cellular-immunity-and-symptomatic-5735ed850a3a066cPharma Surgeen2026-07-01T00:00:00.000ZInnate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infectionhttps://www.pharmaradar360.com/article/a-genome-scale-crispri-perturbation-atlas-of-human-induced-pluripotent-stem-cell-3faf41d96c69e78fPharma Surgeen2026-07-01T00:00:00.000ZA genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cellshttps://www.pharmaradar360.com/article/how-fair-data-are-helping-to-build-trust-in-science-bd2d9f032bf45110Pharma Surgeen2026-07-01T00:00:00.000ZHow FAIR data are helping to build trust in sciencehttps://www.pharmaradar360.com/article/six-ways-to-put-the-public-at-the-heart-of-science-and-policy-bb5c0e3888d5ab56Pharma Surgeen2026-07-01T00:00:00.000ZSix ways to put the public at the heart of science and policyhttps://www.pharmaradar360.com/article/have-people-stopped-trusting-science-the-data-tell-a-surprising-story-506342c633617907Pharma Surgeen2026-07-01T00:00:00.000ZHave people stopped trusting science? The data tell a surprising storyhttps://www.pharmaradar360.com/article/scientists-should-recognize-their-own-political-biases-to-build-public-trust-a85bf80c8f03b023Pharma Surgeen2026-07-01T00:00:00.000ZScientists should recognize their own political biases to build public trusthttps://www.pharmaradar360.com/article/the-complex-truth-about-trust-in-science-666b9d9f077a2d99Pharma Surgeen2026-07-01T00:00:00.000ZThe complex truth about trust in sciencehttps://www.pharmaradar360.com/article/why-paying-peer-reviewers-works-according-to-a-journal-s-editor-in-chief-157b47e82ea3b2f5Pharma Surgeen2026-07-01T00:00:00.000ZWhy paying peer reviewers works, according to a journal’s editor-in-chiefhttps://www.pharmaradar360.com/article/circular-rna-guides-exon-skipping-in-dmd-2dc7e1698550b6bbPharma Surgeen2026-07-01T00:00:00.000ZCircular RNA guides exon skipping in DMDhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-7c64bdc9ee38613bPharma Surgeen2026-07-01T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-cca4d3daa179bf8fPharma Surgeen2026-07-01T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-9b8a118b1c3060d7Pharma Surgeen2026-07-01T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-6ee34af4d561a88dPharma Surgeen2026-07-01T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-2c7398437126c681Pharma Surgeen2026-07-01T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-37ba6e1d0f393fbePharma Surgeen2026-07-01T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-fdb8347c8d9a4893Pharma Surgeen2026-07-01T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-9dea458a8b3d2d02Pharma Surgeen2026-07-01T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-abea927103de2e80Pharma Surgeen2026-07-01T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-66850a936072b4b4Pharma Surgeen2026-07-01T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-86300e230ce9781fPharma Surgeen2026-07-01T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-1dee215d44d7f043Pharma Surgeen2026-07-01T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-cca34484d4eb46f4Pharma Surgeen2026-07-01T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-a6d1c144e71b2fd8Pharma Surgeen2026-07-01T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/more-precise-fire-extinguishing-from-the-air-using-simulation-and-sensor-data-0be4677f1d981cbcPharma Surgeen2026-07-01T00:00:00.000ZMore Precise Fire Extinguishing From the Air Using Simulation and Sensor Datahttps://www.pharmaradar360.com/article/green-lime-reducing-carbon-emissions-in-the-construction-materials-industry-e26357151fcdd281Pharma Surgeen2026-07-01T00:00:00.000ZGreen Lime: Reducing Carbon Emissions in the Construction Materials Industryhttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-temporary-placement-of-5-6-dichloro-brorphine-01846c2ca35e85ccPharma Surgeen2026-07-01T00:00:00.000ZSchedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Acthttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-4bbcaf2d4179db44Pharma Surgeen2026-07-01T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Productshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-ec0fe1e65cfa659bPharma Surgeen2026-07-01T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/lists-of-designated-primary-medical-care-mental-health-and-dental-health-profess-9da79d986a49fa2ePharma Surgeen2026-07-01T00:00:00.000ZLists of Designated Primary Medical Care, Mental Health, and Dental Health Professional Shortage Areashttps://www.pharmaradar360.com/article/notice-of-proposed-purchased-referred-care-delivery-area-redesignation-for-yslet-4760d01d48eca2b2Pharma Surgeen2026-07-01T00:00:00.000ZNotice of Proposed Purchased/Referred Care Delivery Area Redesignation for Ysleta Del Sur Pueblohttps://www.pharmaradar360.com/article/modification-of-living-organ-donation-reimbursement-program-eligibility-guidelin-17d3099fdb331868Pharma Surgeen2026-07-01T00:00:00.000ZModification of Living Organ Donation Reimbursement Program Eligibility Guidelines in Response To Honor Our Living Donors Acthttps://www.pharmaradar360.com/article/the-federal-demonstration-partnership-phase-viii-notice-8f65a17e29bbe00aPharma Surgeen2026-07-01T00:00:00.000ZThe Federal Demonstration Partnership; Phase VIII Noticehttps://www.pharmaradar360.com/article/rural-health-innovation-and-transformation-technical-assistance-8fcfeb01fe6f47d6Pharma Surgeen2026-07-01T00:00:00.000ZRural Health Innovation and Transformation Technical Assistancehttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-cc2c9f220cf027c7Pharma Surgeen2026-07-01T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: National Marrow Donor Program Patient Support Center Surveyhttps://www.pharmaradar360.com/article/drug-label-update-evereden-kids-mineral-sunscreen-spf-30-bd2e8f7ef3f473aaPharma Surgeen2026-07-01T00:00:00.000ZDrug label update: Evereden Kids Mineral Sunscreen SPF 30https://www.pharmaradar360.com/article/drug-label-update-metformin-hydrochloride-046d4a31cf7b826fPharma Surgeen2026-07-01T00:00:00.000ZDrug label update: METFORMIN HYDROCHLORIDEhttps://www.pharmaradar360.com/article/drug-label-update-guna-virus-3eb3bf9cba150338Pharma Surgeen2026-07-01T00:00:00.000ZDrug label update: GUNA-VIRUShttps://www.pharmaradar360.com/article/drug-label-update-metformin-hydrochloride-er-6fc4ef2014cdb350Pharma Surgeen2026-07-01T00:00:00.000ZDrug label update: METFORMIN HYDROCHLORIDE ERhttps://www.pharmaradar360.com/article/ki-forskare-tilldelas-internationellt-stipendium-for-melanomforskning-0e1ccebcdba9eda4Pharma Surgeen2026-07-01T00:00:00.000ZKI‑forskare tilldelas internationellt stipendium för melanomforskninghttps://www.pharmaradar360.com/article/2026-217995372bfaad9bPharma Surgeen2026-07-01T00:00:00.000Z「2026年度 参天製薬奨学寄付プログラム」の募集は終了しましたhttps://www.pharmaradar360.com/article/impact-of-information-leakage-in-platform-trials-with-survival-endpoints-on-type-1579687388622871Pharma Surgeen2026-07-01T00:00:00.000ZImpact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.https://www.pharmaradar360.com/article/timing-of-health-technology-assessment-in-the-united-states-an-evaluation-of-ice-1ca61742b05b2140Pharma Surgeen2026-07-01T00:00:00.000ZTiming of health technology assessment in the United States: An evaluation of ICER reviews over 8 years.https://www.pharmaradar360.com/article/protected-time-for-clinical-investigators-in-medical-oncology-the-persistent-gap-81a381a9c4fd6714Pharma Surgeen2026-07-01T00:00:00.000Z"Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and reality.https://www.pharmaradar360.com/article/rejoinder-to-commentaries-on-a-perspective-on-the-appropriate-implementation-of-f0111ddb640f508fPharma Surgeen2026-07-01T00:00:00.000ZRejoinder to Commentaries on "A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events".https://www.pharmaradar360.com/article/aligning-approaches-to-rheumatoid-arthritis-drug-development-a-comparison-of-fda-26986845616f2761Pharma Surgeen2026-07-01T00:00:00.000ZAligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance.https://www.pharmaradar360.com/article/benzbromarone-as-a-novel-candidate-for-preventing-alzheimer-s-disease-evidence-f-ab2c4b7aaaa37676Pharma Surgeen2026-07-01T00:00:00.000ZBenzbromarone as a Novel Candidate for Preventing Alzheimer's Disease: Evidence From Real-World Data Screening and in Vitro Validation.https://www.pharmaradar360.com/article/differential-impacts-of-methadone-and-buprenorphine-naloxone-on-pain-related-out-212d27082b937b85Pharma Surgeen2026-07-01T00:00:00.000ZDifferential Impacts of Methadone and Buprenorphine/Naloxone on Pain-Related Outcomes Among People With Non-Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial.https://www.pharmaradar360.com/article/pmx-coveval-a-framework-including-a-simulated-pharmacokinetic-database-for-covar-b9009d582cb3f9cePharma Surgeen2026-07-01T00:00:00.000ZPMX-CovEval: A Framework Including a Simulated Pharmacokinetic Database for Covariate Model Building Methods Benchmarking.https://www.pharmaradar360.com/article/optimizing-randomization-ratios-in-clinical-trials-with-survival-endpoints-e7464705b3a8fc33Pharma Surgeen2026-07-01T00:00:00.000ZOptimizing Randomization Ratios in Clinical Trials With Survival Endpoints.https://www.pharmaradar360.com/article/fgf2-in-the-regulation-of-regenerative-repair-and-fibrosis-tgf-cross-talk-and-th-5cd754888cfcbf70Pharma Surgeen2026-07-01T00:00:00.000ZFGF2 in the regulation of regenerative repair and fibrosis: TGF-β cross-talk and therapeutic advances.https://www.pharmaradar360.com/article/effects-of-norbixin-on-growth-performance-immunomodulation-antioxidant-systems-a-a4a405f962503a29Pharma Surgeen2026-07-01T00:00:00.000ZEffects of Norbixin on Growth Performance, Immunomodulation, Antioxidant Systems, and Metabolic Alterations in the Oriental River Prawn (Macrobrachium nipponense): An Integrative Analysis.https://www.pharmaradar360.com/article/the-imperative-of-involving-nurses-when-reviewing-psychiatric-medication-a-quali-a564d762f4a085edPharma Surgeen2026-07-01T00:00:00.000ZThe Imperative of Involving Nurses When Reviewing Psychiatric Medication: a Qualitative Study of Implementing Physician-Led Medication Reviews for Psychiatric Outpatients With Diabetes.https://www.pharmaradar360.com/article/experiences-of-a-pre-treatment-sober-month-in-individuals-with-alcohol-use-disor-32f7cfe2babe35a8Pharma Surgeen2026-07-01T00:00:00.000ZExperiences of a Pre-Treatment Sober Month in Individuals With Alcohol Use Disorder Pursuing Controlled Drinking Goals.https://www.pharmaradar360.com/article/correction-differences-in-drug-efficacy-and-prognosis-between-primary-and-metast-72b75a276267e305Pharma Surgeen2026-07-01T00:00:00.000ZCorrection: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.https://www.pharmaradar360.com/article/short-term-comparative-effects-of-semaglutide-either-alone-or-in-conjunction-wit-6e2b252d3ed3f30cPharma Surgeen2026-07-01T00:00:00.000ZShort-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.https://www.pharmaradar360.com/article/a-knowledge-base-of-designs-and-statistical-methods-for-adaptive-clinical-dose-f-43e11ba329f45863Pharma Surgeen2026-07-01T00:00:00.000ZA Knowledge Base of Designs and Statistical Methods for Adaptive Clinical Dose-Finding Trials.https://www.pharmaradar360.com/article/clinical-outcomes-of-terlipressin-using-continuous-infusion-versus-bolus-in-pati-e0bcbeb53b578139Pharma Surgeen2026-07-01T00:00:00.000ZClinical Outcomes of Terlipressin Using Continuous Infusion Versus Bolus in Patients With Acute Variceal Hemorrhage-A Randomized Controlled Trial.https://www.pharmaradar360.com/article/early-response-driven-tooth-survival-prognostication-after-periodontal-therapy-a-0fffaf9b20edabc3Pharma Surgeen2026-07-01T00:00:00.000ZEarly Response-driven Tooth Survival Prognostication after Periodontal Therapy: A Cox-based Machine Learning Survival Modelhttps://www.pharmaradar360.com/article/systemic-immune-inflammatory-index-and-systemic-inflammatory-response-index-in-i-7ecc8309df43e770Pharma Surgeen2026-07-01T00:00:00.000ZSystemic Immune Inflammatory Index and Systemic Inflammatory Response Index in Invasive Ductal Carcinoma of the Breast and their Association with Molecular Types, Grade and Stage of Disease: A Cross-sectional Studyhttps://www.pharmaradar360.com/article/comparison-of-estimated-glomerular-filtration-rate-from-venous-and-umbilical-cor-3489b9f302f30439Pharma Surgeen2026-07-01T00:00:00.000ZComparison of Estimated Glomerular Filtration Rate from Venous and Umbilical Cord Blood in Preterm and Low-birth-weight Neonates using Creatinine and Cystatin-C: A Case-control Studyhttps://www.pharmaradar360.com/article/emotional-availability-in-nursing-a-concept-analysis-of-its-impact-on-patient-ou-a7a846aa7c9d9e69Pharma Surgeen2026-07-01T00:00:00.000ZEmotional availability in nursing: A concept analysis of its impact on patient outcomeshttps://www.pharmaradar360.com/article/evaluating-household-pharmaceutical-waste-systems-in-albania-and-the-european-un-74c3dc2238ea5ab6Pharma Surgeen2026-07-01T00:00:00.000ZEvaluating household pharmaceutical waste systems in Albania and the European Union: A comparative studyhttps://www.pharmaradar360.com/article/impact-of-parents-expressed-emotions-on-clinical-manifestations-and-quality-of-l-694ef760f528d783Pharma Surgeen2026-07-01T00:00:00.000ZImpact of Parents' Expressed Emotions on Clinical Manifestations and Quality of Life among Patients with Bipolar Disorder.https://www.pharmaradar360.com/article/role-of-microrna-223-and-high-mobility-group-box-1-as-predictors-of-drug-resista-64593eddff749ca5Pharma Surgeen2026-07-01T00:00:00.000ZRole of microRNA-223 and High Mobility Group box 1 as Predictors of Drug-resistant Epilepsyhttps://www.pharmaradar360.com/article/association-between-ureteral-jet-angle-by-color-doppler-ultrasonography-and-the-4da34b542a1f5b33Pharma Surgeen2026-07-01T00:00:00.000ZAssociation Between Ureteral Jet Angle by Color Doppler Ultrasonography and the Clinical Outcomes of Vesicoureteral Refluxhttps://www.pharmaradar360.com/article/accommodation-in-myopic-children-wearing-individualized-ocular-refraction-custom-8c6d8af303782870Pharma Surgeen2026-07-01T00:00:00.000ZAccommodation in myopic children wearing individualized ocular refraction customization spectacle lenses: Results from a randomized clinical trialhttps://www.pharmaradar360.com/article/factors-associated-with-employment-and-hospitalizations-in-early-onset-psychosis-6bd36c912c951965Pharma Surgeen2026-07-01T00:00:00.000ZFactors associated with employment and hospitalizations in early-onset psychosis: a clinical study with register-based follow-uphttps://www.pharmaradar360.com/article/added-value-of-restricted-diffusion-in-acute-pyelonephritis-two-cases-with-diffe-29830d5da0c62d34Pharma Surgeen2026-07-01T00:00:00.000ZAdded value of restricted diffusion in acute pyelonephritis: Two cases with different clinical presentationshttps://www.pharmaradar360.com/article/effectiveness-of-a-blended-in-person-and-online-parenting-programme-in-reducing-36abc97504515bc6Pharma Surgeen2026-07-01T00:00:00.000ZEffectiveness of a blended in-person and online parenting programme in reducing violence against children in rural Thailand: a cluster randomised controlled trialhttps://www.pharmaradar360.com/article/development-of-a-ms-binding-assay-to-analyze-the-interactions-of-drugs-with-the-0f2254f159762139Pharma Surgeen2026-07-01T00:00:00.000ZDevelopment of a MS binding assay to analyze the interactions of drugs with the ifenprodil binding site of NMDA receptors with GluN2B subunithttps://www.pharmaradar360.com/article/layered-suspension-fixation-and-comprehensive-management-prevent-subcutaneous-ef-6d51473ebbe61224Pharma Surgeen2026-07-01T00:00:00.000ZLayered suspension fixation and comprehensive management prevent subcutaneous effusion after polyetheretherketone cranioplasty: A retrospective case serieshttps://www.pharmaradar360.com/article/research-progress-from-traditional-medicine-to-chemical-composition-pharmacologi-5b048085d1eb0024Pharma Surgeen2026-07-01T00:00:00.000ZResearch progress from traditional medicine to chemical composition, pharmacological activity, and clinical application of Rhodiola crenulatahttps://www.pharmaradar360.com/article/sustained-co-delivery-of-parecoxib-and-cisplatin-via-a-biodegradable-thermosensi-3cd6bd743169ec86Pharma Surgeen2026-07-01T00:00:00.000ZSustained co-delivery of Parecoxib and cisplatin via a biodegradable thermosensitive hydrogel for preoperative synergistic combination chemotherapy in triple-negative breast cancerhttps://www.pharmaradar360.com/article/engineering-and-evaluation-of-polyethylenimine-decorated-maghemite-poli-caprolac-59648290dbec475cPharma Surgeen2026-07-01T00:00:00.000ZEngineering and evaluation of polyethylenimine-decorated maghemite/poli(ε-caprolactone) (core/shell) nanoparticles: colloidal stability, safety, biodistribution and tumor targeting capabilitieshttps://www.pharmaradar360.com/article/polymer-selection-in-amorphous-solid-dispersions-from-stabilization-mechanisms-t-6bdcb4b2b7432319Pharma Surgeen2026-07-01T00:00:00.000ZPolymer selection in amorphous solid dispersions: From stabilization mechanisms to marketed drug productshttps://www.pharmaradar360.com/article/effect-of-adding-median-nerve-mobilization-to-glenohumeral-joint-mobilization-in-8d2d4076fd11f5d8Pharma Surgeen2026-07-01T00:00:00.000ZEffect of adding median nerve mobilization to glenohumeral joint mobilization in patients with adhesive Capsulitis. Randomized controlled trialhttps://www.pharmaradar360.com/article/towards-reliable-clinical-data-a-collaborative-data-governance-architecture-with-438d5eefbc839f28Pharma Surgeen2026-07-01T00:00:00.000ZTowards Reliable Clinical Data: A Collaborative Data Governance Architecture with Lifecycle Integrationhttps://www.pharmaradar360.com/article/immunoglobulin-replacement-therapy-in-primary-immunodeficiency-disorders-pragmat-81ae812706f2af9ePharma Surgeen2026-07-01T00:00:00.000ZImmunoglobulin replacement therapy in primary immunodeficiency disorders: Pragmatic review and evidence mappinghttps://www.pharmaradar360.com/article/functionalized-magnetic-nanomaterials-for-pharmaceutical-contaminant-removal-mec-4986294298fd8c3cPharma Surgeen2026-07-01T00:00:00.000ZFunctionalized magnetic nanomaterials for pharmaceutical contaminant removal: Mechanisms and applicationshttps://www.pharmaradar360.com/article/artificial-intelligence-in-oral-and-maxillofacial-surgery-a-scoping-review-of-cl-aee276cad4381a77Pharma Surgeen2026-07-01T00:00:00.000ZArtificial intelligence in oral and maxillofacial surgery: a scoping review of clinical applications, ethical challenges, and legal considerationshttps://www.pharmaradar360.com/article/artificial-intelligence-in-gastroenterology-clinical-practice-scoping-review-of-6434310b0b516bf8Pharma Surgeen2026-07-01T00:00:00.000ZArtificial intelligence in gastroenterology clinical practice: Scoping review of large language model applicationshttps://www.pharmaradar360.com/article/admission-without-consent-to-a-psychiatric-ward-and-length-of-hospital-stay-the-adbabb5a054781ddPharma Surgeen2026-07-01T00:00:00.000ZAdmission without consent to a psychiatric ward and length of hospital stay: The role of selected sociodemographic and clinical factorshttps://www.pharmaradar360.com/article/are-gaps-in-the-time-of-submissions-and-approvals-of-new-drugs-between-health-ca-a5d31bcef33b7ef4Pharma Surgeen2026-07-01T00:00:00.000ZAre gaps in the time of submissions and approvals of new drugs between Health Canada and the Food and Drug Administration related to therapeutic value? A cross-sectional studyhttps://www.pharmaradar360.com/article/exposure-response-modeling-of-qtc-interval-and-creatine-kinase-mb-in-healthy-peo-cb1365b7c519d5c1Pharma Surgeen2026-07-01T00:00:00.000ZExposure–response modeling of QTc interval and creatine kinase-MB in healthy people and treatment-naïve adults living with HIV-1 treated with ainuovirine monotherapy or combined with lamivudine and tenofovir DFhttps://www.pharmaradar360.com/article/pelvic-muscle-training-and-electrostimulation-to-treat-weak-pelvic-floor-a-multi-78f5e404e69d62c7Pharma Surgeen2026-07-01T00:00:00.000ZPelvic muscle training and electrostimulation to treat weak pelvic floor: a multicentre-randomised parallel group trialhttps://www.pharmaradar360.com/article/a-multidisciplinary-expert-consensus-framework-for-diabetic-foot-disease-managem-00d47f0bdb8553b6Pharma Surgeen2026-07-01T00:00:00.000ZA multidisciplinary expert consensus framework for diabetic foot disease management in the Gulf Cooperation Council: A modified Delphi studyhttps://www.pharmaradar360.com/article/integrative-proteogenomic-analyses-implicate-klk13-as-a-glycaemia-linked-circula-223ee23be535cad1Pharma Surgeen2026-07-01T00:00:00.000ZIntegrative proteogenomic analyses implicate KLK13 as a glycaemia-linked circulating protein in diabetic kidney diseasehttps://www.pharmaradar360.com/article/health-promotion-pharmaceutical-training-and-public-health-a-scoping-review-on-r-5bad484c9c7a76c1Pharma Surgeen2026-07-01T00:00:00.000ZHealth promotion, pharmaceutical training and public health: A scoping review on readiness and competencies in studies with students and professionalshttps://www.pharmaradar360.com/article/outdoor-therapies-delivered-by-mental-health-professionals-a-scoping-review-of-c-77ef39e7c94aafebPharma Surgeen2026-07-01T00:00:00.000ZOutdoor therapies delivered by mental health professionals: A scoping review of clinical trialshttps://www.pharmaradar360.com/article/effectiveness-of-portable-digital-nature-experience-on-mental-health-a-three-lev-0d73d5d1ac4a2633Pharma Surgeen2026-07-01T00:00:00.000ZEffectiveness of portable digital nature experience on mental health: A three-level meta-analysis of randomized controlled trialshttps://www.pharmaradar360.com/article/bridging-the-gap-between-robotic-spine-surgery-and-resource-limited-settings-ins-fc5c5b44618b427dPharma Surgeen2026-07-01T00:00:00.000ZBridging the gap between robotic spine surgery and resource-limited settings: Insights from Indonesiahttps://www.pharmaradar360.com/article/technique-of-performing-an-epidural-blood-patch-in-spontaneous-intracranial-hypo-c88f83e09a773531Pharma Surgeen2026-07-01T00:00:00.000ZTechnique of performing an epidural blood patch in spontaneous intracranial hypotension due to cerebrospinal fluid leakage from the nerve root sheath: Case serieshttps://www.pharmaradar360.com/article/biopolymeric-micro-and-nanoscale-colloidal-delivery-systems-for-controlled-drug-669443a9002a9bbaPharma Surgeen2026-07-01T00:00:00.000ZBiopolymeric micro and nanoscale colloidal delivery systems for controlled drug release in pharmaceutical sectorhttps://www.pharmaradar360.com/article/reader-comment-regarding-achieved-blood-pressure-during-the-first-12-h-and-clini-763a654a68ec050aPharma Surgeen2026-07-01T00:00:00.000ZReader comment regarding “Achieved blood pressure during the first 12 h and clinical outcomes in patients with out-of-hospital cardiac arrest”https://www.pharmaradar360.com/article/rationale-and-design-of-a-pragmatic-randomized-clinical-trial-assessing-a-smartp-491f7480a8c39de7Pharma Surgeen2026-07-01T00:00:00.000ZRationale and design of a pragmatic randomized clinical trial assessing a smartphone-based digital health intervention in hypertension: The ELFIE-HYPERTENSION trialhttps://www.pharmaradar360.com/article/advances-in-lung-on-a-chip-platforms-for-nanotherapeutic-evaluation-and-screenin-12209be8af2b9413Pharma Surgeen2026-07-01T00:00:00.000ZAdvances in lung-on-a-chip platforms for nanotherapeutic evaluation and screeninghttps://www.pharmaradar360.com/article/a-bioinformatics-guided-analytical-approach-for-drug-repositioning-colchicine-as-8d3f999fe13bec88Pharma Surgeen2026-07-01T00:00:00.000ZA bioinformatics-guided analytical approach for drug repositioning: Colchicine as a candidate for gaucher disease treatmenthttps://www.pharmaradar360.com/article/aptose-biosciences-announces-completion-of-acquisition-by-hanmi-pharmaceutical-04130eddcdd160c7Pharma Surgeen2026-06-30T23:32:00.000ZAptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceuticalhttps://www.pharmaradar360.com/article/teen-cancer-survivor-travels-6-000-miles-from-cyprus-for-life-changing-care-cele-a62af3adaf17e639Pharma Surgeen2026-06-30T23:24:51.000ZTeen Cancer Survivor Travels 6,000 Miles from Cyprus for Life‑changing Care, Celebrated with Chicago-style Deep Dish Sendoffhttps://www.pharmaradar360.com/article/ai-company-anthropic-announces-it-will-begin-developing-drugs-of-its-own-ade396d106f1a7daPharma Surgeen2026-06-30T23:21:11.000ZAI company Anthropic announces it will begin developing drugs of its ownhttps://www.pharmaradar360.com/article/american-heart-association-launches-first-libraries-with-heart-site-in-northwest-5f3c123c94c55092Pharma Surgeen2026-06-30T23:17:00.000ZAmerican Heart Association launches first Libraries with Heart site in Northwest Arkansas at West Fork Public Libraryhttps://www.pharmaradar360.com/article/billions-of-doses-later-global-review-confirms-mrna-vaccines-are-safe-effective-b658a145e087f1bbPharma Surgeen2026-06-30T22:30:00.000ZBillions of doses later: Global review confirms mRNA vaccines are safe, effective and full of promisehttps://www.pharmaradar360.com/article/circulation-descubren-un-mecanismo-clave-en-el-desarrollo-del-dano-coronario-aso-4215d96dec3c9cf8Pharma Surgeen2026-06-30T22:00:00.000ZCirculation: Descubren un mecanismo clave en el desarrollo del daño coronario asociado a la enfermedad de Kawasakihttps://www.pharmaradar360.com/article/northwestern-medicine-research-shows-multi-disciplinary-treatment-improves-survi-e13bf52c066a35a5Pharma Surgeen2026-06-30T21:52:28.000ZNorthwestern Medicine Research Shows Multi-Disciplinary Treatment Improves Survival and Quality of Life for Older Patients with Brain Cancerhttps://www.pharmaradar360.com/article/cmc-hurdles-stall-korea-drug-approvals-as-kddf-and-kcmc-mobilize-support-chosunb-0f3156a0236bf632Pharma Surgeen2026-06-30T21:46:00.000ZCMC hurdles stall Korea drug approvals as KDDF and KCMC mobilize support - CHOSUNBIZhttps://www.pharmaradar360.com/article/diabetes-dialogue-tegoprubart-and-freedom-from-insulin-in-type-1-diabetes-cbb4568001ca4092Pharma Surgeen2026-06-30T21:45:42.000ZDiabetes Dialogue: Tegoprubart and Freedom from Insulin in Type 1 Diabeteshttps://www.pharmaradar360.com/article/uncy-stock-clocks-worst-day-in-a-year-analysts-keep-buy-ratings-despite-5-12-mon-4a0f7434a8b8b1dePharma Surgeen2026-06-30T21:34:20.000ZUNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approvalhttps://www.pharmaradar360.com/article/this-pharmaceutical-giant-just-poured-11-billion-on-an-acquisition-time-to-buy-7cd26c22682a3324Pharma Surgeen2026-06-30T20:45:00.000ZThis Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?https://www.pharmaradar360.com/article/jovenes-becarios-de-investigacion-tuvieron-su-acto-de-bienvenida-96c945372bb5d8b4Pharma Surgeen2026-06-30T20:44:33.000ZJóvenes becarios de investigación tuvieron su acto de bienvenidahttps://www.pharmaradar360.com/article/made-in-canada-why-local-cold-chain-manufacturing-matters-d9b63b24cad0caf9Pharma Surgeen2026-06-30T20:42:43.000ZMade in Canada: Why Local Cold Chain Manufacturing Mattershttps://www.pharmaradar360.com/article/pediatric-clinical-trial-update-june-2026-04046d78a9ffc949Pharma Surgeen2026-06-30T20:42:07.000ZPediatric clinical trial update: June 2026https://www.pharmaradar360.com/article/quick-action-by-family-ems-and-intermountain-health-caregivers-saves-life-of-mon-995d455d877ebe4aPharma Surgeen2026-06-30T20:20:37.000ZQuick Action by Family, EMS, and Intermountain Health Caregivers Saves Life of Montana Mother After Cardiac Arresthttps://www.pharmaradar360.com/article/prativa-baral-awarded-cihr-s-steps-team-grant-368656e8c728dbd8Pharma Surgeen2026-06-30T20:15:34.000ZPrativa Baral awarded CIHR’s STEPS Team Granthttps://www.pharmaradar360.com/article/labcorp-to-announce-second-quarter-2026-financial-results-on-july-30-2026-56475dd8fb2373ebPharma Surgeen2026-06-30T20:15:00.000ZLabcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026https://www.pharmaradar360.com/article/global-clinical-trial-reveals-safest-most-effective-antibiotics-for-staphylococc-6f5992d4670b4e9ePharma Surgeen2026-06-30T20:05:43.000ZGlobal clinical trial reveals safest, most effective antibiotics for staphylococcal bloodstream infectionshttps://www.pharmaradar360.com/article/entrega-de-la-beca-tu-pc-para-estudiar-a-estudiantes-liberados-03e7a7c0260af192Pharma Surgeen2026-06-30T19:55:20.000ZEntrega de la Beca “Tu PC para estudiar” a estudiantes liberadoshttps://www.pharmaradar360.com/article/help-stock-crashes-on-anxiety-trial-results-but-here-s-why-jefferies-sees-up-to-145d42874ac0b13fPharma Surgeen2026-06-30T19:53:42.000ZHELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upsidehttps://www.pharmaradar360.com/article/delaware-judge-tosses-biotech-exec-s-700m-suit-over-failed-ipo-76d6929f889e98bcPharma Surgeen2026-06-30T19:40:00.000ZDelaware Judge Tosses Biotech Exec.'s $700M Suit Over Failed IPOhttps://www.pharmaradar360.com/article/anthropic-releases-claude-science-a-product-aimed-at-researchers-the-pharma-indu-99db3fdfc6d9b4c6Pharma Surgeen2026-06-30T19:35:21.000ZAnthropic releases Claude Science, a product aimed at researchers, the pharma industryhttps://www.pharmaradar360.com/article/5-key-principles-of-modern-pk-pd-in-2026-5389bb69eb4f4c71Pharma Surgeen2026-06-30T19:24:29.000Z5 Key Principles of Modern PK/PD in 2026https://www.pharmaradar360.com/article/regenxbio-doses-first-patient-in-naavigate-phase-2b-3-sura-vec-trial-for-diabeti-50f2e28d8c11eca4Pharma Surgeen2026-06-30T19:19:38.000ZREGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathyhttps://www.pharmaradar360.com/article/gerren-mcham-on-the-future-of-us-pharma-reshoring-f805a3c33dc13d07Pharma Surgeen2026-06-30T19:09:28.000ZGerren McHam on the Future of US Pharma Reshoringhttps://www.pharmaradar360.com/article/fda-approves-new-ted-drug-for-active-and-chronic-phases-b60d49242b8a2edfPharma Surgeen2026-06-30T19:07:14.000ZFDA Approves New TED Drug for Active and Chronic Phaseshttps://www.pharmaradar360.com/article/bio-2026-biotech-fundraising-rises-as-company-pipelines-mature-2bbde369690380baPharma Surgeen2026-06-30T18:54:13.000ZBIO 2026: Biotech Fundraising Rises As Company Pipelines Maturehttps://www.pharmaradar360.com/article/fda-names-seven-participants-to-precheck-program-pharmexec-18a908c7a614821cPharma Surgeen2026-06-30T18:46:08.000ZFDA Names Seven Participants to Precheck Program | PharmExechttps://www.pharmaradar360.com/article/ever-supreme-advances-off-the-shelf-car-t-therapy-car001-to-phase-iia-after-posi-47867ef3c424aebcPharma Surgeen2026-06-30T18:33:53.000ZEver Supreme Advances Off-the-Shelf CAR-T Therapy CAR001 to Phase IIa After Positive Phase I Safety Reviewhttps://www.pharmaradar360.com/article/new-tool-maps-public-land-with-potential-for-hundreds-of-thousands-of-affordable-7ecf98bf9f5e4176Pharma Surgeen2026-06-30T18:30:00.000ZNew tool maps public land with potential for hundreds of thousands of affordable homes in B.C.https://www.pharmaradar360.com/article/sun-life-extends-collaboration-with-the-american-diabetes-association-to-continu-a7bb38091e441d62Pharma Surgeen2026-06-30T18:25:39.000ZSun Life extends collaboration with the American Diabetes Association to continue support of youth initiative Project Powerhttps://www.pharmaradar360.com/article/umsop-professor-richard-dalby-retires-after-34-years-of-leadership-in-pharmaceut-d65b2ee4abc11040Pharma Surgeen2026-06-30T18:24:23.000ZUMSOP Professor Richard Dalby Retires After 34 Years of Leadership in Pharmaceutical Scienceshttps://www.pharmaradar360.com/article/recent-research-on-how-experiencing-racial-discrimination-impacts-health-507ab1bb0b8c481ePharma Surgeen2026-06-30T18:22:17.000ZRecent Research on How Experiencing Racial Discrimination Impacts Healthhttps://www.pharmaradar360.com/article/men-s-health-month-an-opportunity-to-strengthen-preventive-care-engagement-5088d9c2de413945Pharma Surgeen2026-06-30T18:14:52.000ZMen’s Health Month: An Opportunity to Strengthen Preventive Care Engagementhttps://www.pharmaradar360.com/article/charlas-del-veni-a-la-unlp-f61b54ab5e9d0312Pharma Surgeen2026-06-30T18:08:04.000ZCharlas del Vení a la UNLPhttps://www.pharmaradar360.com/article/forum-debate-os-caminhos-da-ciencia-e-da-inovacao-para-construir-o-brasil-de-205-ccb01cfd4a9d0cf5Pharma Surgeen2026-06-30T18:06:50.000ZFórum debate os caminhos da ciência e da inovação para construir o Brasil de 2050https://www.pharmaradar360.com/article/pharmaceutical-company-closing-birmingham-facility-fb0e8e29977eb2fbPharma Surgeen2026-06-30T17:33:00.000ZPharmaceutical company closing Birmingham facilityhttps://www.pharmaradar360.com/article/these-tar-heels-are-working-the-world-cup-c4f0c183d9db2661Pharma Surgeen2026-06-30T17:28:33.000ZThese Tar Heels are working the World Cuphttps://www.pharmaradar360.com/article/oportunidad-de-movilidad-estudiantil-en-la-universidad-privada-de-tacna-upt-e89c218f57d32b50Pharma Surgeen2026-06-30T17:27:37.000ZOportunidad de movilidad estudiantil en la Universidad Privada de Tacna (UPT)https://www.pharmaradar360.com/article/el-consejo-superior-definio-la-composicion-del-gabinete-de-gestion-2026-2030-ce953bf0480a5aa6Pharma Surgeen2026-06-30T17:09:05.000ZEl Consejo Superior definió la composición del gabinete de gestión 2026-2030https://www.pharmaradar360.com/article/media-outlets-cover-passing-of-scripps-innovator-a-brent-eastman-md-3cf90a2415b7d303Pharma Surgeen2026-06-30T17:08:34.000ZMedia Outlets Cover Passing of Scripps Innovator A. Brent Eastman, MDhttps://www.pharmaradar360.com/article/la-palabra-universitaria-vuelve-a-circular-f1f2ba1c0e7cc9faPharma Surgeen2026-06-30T17:07:49.000ZLa Palabra Universitaria vuelve a circularhttps://www.pharmaradar360.com/article/unlp-y-conicet-presentaron-un-documento-al-municipio-sobre-el-reciclado-752b83e4d76acccfPharma Surgeen2026-06-30T17:07:46.000ZUNLP y CONICET presentaron un documento al Municipio sobre el Recicladohttps://www.pharmaradar360.com/article/uc-irvine-astronomers-discover-a-new-earth-like-exoplanet-8e5c19125cb0e5f7Pharma Surgeen2026-06-30T17:02:01.000ZUC Irvine astronomers discover a new Earth-like exoplanethttps://www.pharmaradar360.com/article/apple-creator-studio-gets-smarter-faster-and-more-connected-2f242da8a81f621dPharma Surgeen2026-06-30T16:59:24.000ZApple Creator Studio gets smarter, faster, and more connectedhttps://www.pharmaradar360.com/article/convocatoria-acreditacion-de-proyectos-i-d-y-ppid-2027-30fd8a04a4193e0ePharma Surgeen2026-06-30T16:55:33.000ZCONVOCATORIA| Acreditación de Proyectos I+D y PPID 2027https://www.pharmaradar360.com/article/candel-therapeutics-initiates-phase-3-lung-cancer-trial-by-investing-com-740c23e1dbee0c18Pharma Surgeen2026-06-30T16:47:23.000ZCandel Therapeutics initiates phase 3 lung cancer trial By Investing.comhttps://www.pharmaradar360.com/article/bridging-in-vitro-and-in-vivo-solubility-strategies-for-modified-release-success-5e2c58fed248d71dPharma Surgeen2026-06-30T16:46:06.000ZBridging In Vitro and In Vivo: Solubility Strategies for Modified Release Successhttps://www.pharmaradar360.com/article/does-quotient-sciences-have-uk-facilities-c105efc501adc61aPharma Surgeen2026-06-30T16:41:57.000ZDoes Quotient Sciences have UK facilities?https://www.pharmaradar360.com/article/does-quotient-sciences-have-us-facilities-db7b2eed96144a8fPharma Surgeen2026-06-30T16:41:08.000ZDoes Quotient Sciences have US facilities?https://www.pharmaradar360.com/article/manufacturing-deficiencies-behind-fda-s-oxylanthanum-carbonate-rejection-c88ad079548571eePharma Surgeen2026-06-30T16:40:09.000ZManufacturing Deficiencies Behind FDA's Oxylanthanum Carbonate Rejectionhttps://www.pharmaradar360.com/article/many-pharmaceutical-active-ingredients-can-switch-to-pfas-free-alternatives-cb1a656f280091f1Pharma Surgeen2026-06-30T16:38:00.000ZMany pharmaceutical active ingredients can switch to PFAS-free alternativeshttps://www.pharmaradar360.com/article/fda-to-hire-2-200-staffers-as-it-narrows-search-for-commissioner-names-produce-s-e9c5fbc2ac3786b6Pharma Surgeen2026-06-30T16:33:25.000ZFDA to Hire 2,200 Staffers as it Narrows Search for Commissioner, Names Produce Safety Directorhttps://www.pharmaradar360.com/article/se-puso-en-marcha-el-tren-sanitario-de-la-unlp-dd3480f81ea0c156Pharma Surgeen2026-06-30T16:31:22.000ZSe puso en marcha el Tren Sanitario de la UNLPhttps://www.pharmaradar360.com/article/la-unlp-y-china-afianzan-lazos-de-cooperacion-con-la-inauguracion-de-un-nuevo-ce-4d5fdc5cca806ad2Pharma Surgeen2026-06-30T16:26:12.000ZLa UNLP y China afianzan lazos de cooperación con la inauguración de un nuevo centro culturalhttps://www.pharmaradar360.com/article/un-craneo-de-66-millones-de-anos-revela-la-historia-de-un-reptil-marino-patagoni-8560c9484c0a9a61Pharma Surgeen2026-06-30T16:25:38.000ZUn cráneo de 66 millones de años revela la historia de un reptil marino patagónicohttps://www.pharmaradar360.com/article/orgullo-maria-delfina-sciutto-se-graduo-con-honores-en-derecho-y-fue-premiada-po-ec440a6021b763f6Pharma Surgeen2026-06-30T16:24:16.000ZOrgullo: María Delfina Sciutto se graduó con honores en Derecho y fue premiada por la Corte Supremahttps://www.pharmaradar360.com/article/artrosis-canina-desarrollan-un-tratamiento-a-base-de-cartilago-de-tiburon-e59f38c3f467adf5Pharma Surgeen2026-06-30T16:21:16.000ZArtrosis canina: desarrollan un tratamiento a base de cartílago de tiburónhttps://www.pharmaradar360.com/article/candel-therapeutics-stock-gains-on-launch-of-phase-3-trial-for-lung-cancer-drug-ea454999c7a186aaPharma Surgeen2026-06-30T16:12:18.000ZCandel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drughttps://www.pharmaradar360.com/article/improving-clinical-trial-site-collaboration-with-connected-study-startup-workflo-da3f9130544e6465Pharma Surgeen2026-06-30T16:10:58.000ZImproving Clinical Trial Site Collaboration with Connected Study Startup Workflowshttps://www.pharmaradar360.com/article/fda-selects-seven-pharmaceutical-companies-for-precheck-supply-chain-pilot-progr-0a2c6d79644ccb92Pharma Surgeen2026-06-30T16:07:47.000ZFDA Selects Seven Pharmaceutical Companies for PreCheck Supply Chain Pilot Programhttps://www.pharmaradar360.com/article/ean-2026-new-fintepla-data-in-dravet-syndrome-and-lgs-2e1731dabde52e0cPharma Surgeen2026-06-30T16:04:22.000ZEAN 2026: New Fintepla data in Dravet Syndrome and LGShttps://www.pharmaradar360.com/article/pelabresib-from-morphosys-ag-late-stage-blood-cancer-drug-reshapes-the-pipeline-36838041c7585654Pharma Surgeen2026-06-30T16:04:09.000ZPelabresib from MorphoSys AG - late-stage blood cancer drug reshapes the pipelinehttps://www.pharmaradar360.com/article/intermountain-foundation-adds-five-prominent-leaders-to-board-of-trustees-signal-4a9c1c767b095410Pharma Surgeen2026-06-30T16:02:02.000ZIntermountain Foundation Adds Five Prominent Leaders to Board of Trustees, Signaling Momentum for Major Health Care Campaignshttps://www.pharmaradar360.com/article/agc-biologics-expands-to-fill-finish-in-u-s-through-strategic-partnership-with-p-0f5f29f984e37195Pharma Surgeen2026-06-30T16:00:01.000ZAGC Biologics Expands to Fill-Finish in U.S. Through Strategic Partnership with Pyramid Pharma Serviceshttps://www.pharmaradar360.com/article/is-there-a-link-between-faster-ageing-and-early-onset-cancer-risk-f54010f77b76408bPharma Surgeen2026-06-30T15:46:48.000ZIs there a link between faster ageing and early-onset cancer risk?https://www.pharmaradar360.com/article/stoke-completes-phase-3-enrollment-for-dravet-drug-study-6d6da53a723753e5Pharma Surgeen2026-06-30T15:36:01.000ZStoke completes Phase 3 enrollment for Dravet drug studyhttps://www.pharmaradar360.com/article/regina-gerdes-verlasst-das-universitatsspital-zurich-cc085937987258acPharma Surgeen2026-06-30T15:29:18.000ZRegina Gerdes verlässt das Universitätsspital Zürichhttps://www.pharmaradar360.com/article/seven-companies-selected-for-fda-pilot-to-strengthen-us-drug-supply-chain-5fdad739b5437749Pharma Surgeen2026-06-30T15:24:07.000ZSeven Companies Selected for FDA Pilot to Strengthen US Drug Supply Chainhttps://www.pharmaradar360.com/article/imviva-biotech-gains-fda-ide-authorization-for-clonoseq-assay-in-tenacity-01-cli-d9ddbf93a50d7693Pharma Surgeen2026-06-30T15:20:45.000ZImviva Biotech Gains FDA IDE Authorization for clonoSEQ Assay in TENACITY-01 Clinical Trialhttps://www.pharmaradar360.com/article/two-roads-diverged-24f43ad0aa85acddPharma Surgeen2026-06-30T15:13:39.000ZTwo Roads Divergedhttps://www.pharmaradar360.com/article/why-is-unicycive-therapeutics-stock-falling-tuesday-6f7394d18cab19b9Pharma Surgeen2026-06-30T15:04:03.000ZWhy Is Unicycive Therapeutics Stock Falling Tuesday?